BodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes.
VectorY is growing PIONEER-ALS from 12 to 36 participants to test VTx-002, an antibody therapy aimed at the protein TDP-43.
A Censuswide survey commissioned by PortionIQ finds confidence is lower among longer-term users, though it’s a snapshot from one brand.
Forget the diagnosis count. The researcher who helped the WHO reframe aging says function, not disease, is the better yardstick.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results